Prof. Kenneth Cusi, a leading expert in Endocrinology, currently serves as the Chief of the Division of Endocrinology at the University of Florida. Renowned for his groundbreaking work on the correlation between NAFLD and T2DM, Prof. Cusi has published over 150 articles in leading medical journals and received numerous accolades for his contributions to medicine.
Updates in ADA’s 2023 Standard of Care in Diabetes
Explore ADA’s 2023 updates on diabetes care, focusing on non-alcoholic fatty liver disease (NAFLD) and cirrhosis prevention. Learn from Dr. Kenneth Cusi on risk stratification, diagnostic tools like FIB-4, and latest management recommendations.
Read MoreUpdates in ADA’s 2023 Standard of Care in DiabetesManagement of non-alcoholic steatohepatitis (NASH): a multiorgan disease driven by insulin resistance, obesity and T2D
Prof. Rautou, France, discusses a critical component of the diagnosis and management of NASH: biomarkers. There are 2 aspects: fibrosis and diagnosis. Diagnosis is a field of investigations. Microvesicles could play a role.
Read MoreManagement of non-alcoholic steatohepatitis (NASH): a multiorgan disease driven by insulin resistance, obesity and T2DManagement of patients with T2D and NAFLD: the role of PPAR-γ
Exploring the role of PPAR-y in the management of patients with Type 2 Diabetes and NAFLD with Prof. Kenneth Cusi (USA)
Read MoreManagement of patients with T2D and NAFLD: the role of PPAR-γManagement of patients with Type 2 Diabetes (T2DM) and Nonalcoholic Fatty Liver Disease (NAFLD)
Discover the very special relationship between Non-alcoholic fatty liver disease (NAFLD) and Type 2 Diabetes (T2DM) with Prof Kenneth Cusi, USA. Each of these conditions seems to worsen the other.
Read MoreManagement of patients with Type 2 Diabetes (T2DM) and Nonalcoholic Fatty Liver Disease (NAFLD)The role of insulin resistance and insulin-sensitizers in NASH management: tips for the practicing clinician
Prof. Rautou, France, discusses a critical component of the diagnosis and management of NASH: biomarkers. There are 2 aspects: fibrosis and diagnosis. Diagnosis is a field of investigations. Microvesicles could play a role.
Read MoreThe role of insulin resistance and insulin-sensitizers in NASH management: tips for the practicing clinicianThe role of insulin resistance and insulin-sensitizers in NASH management: tips for the practicing clinician
Prof Kenneth Cusi, USA, discusses the role of insulin sensitizers in NASH, and particularly how lifestyle interventions including weight loss can, in this context, be beneficial together with a pharmacological approach.
Read MoreThe role of insulin resistance and insulin-sensitizers in NASH management: tips for the practicing clinicianProf Cusi sheds light on the new exciting information made public at the Liver meeting in Boston
The liver meeting has been fantastic. There’s a lot of…
Prof Kenneth Cusi, USA discusses the role of diabetologists in screening for NASH
So the diabetologists are recognizing that they have to do…
Lipotoxicity in NASH
That’s a very important concept because lipotoxicity is a driver…